The pioneer of innovative proteomic and glycomic research solutions, today announced the acquisitions of Click Chemistry Tools, a manufacturer of click chemistry linkers and labeling

The ERP Biomarker Qualification Consortium announced today the successful completion of a pharma industry-sponsored study to measure the electrophysiologic effects of ketamine on healthy brain function.

ArisGlobal , the leading provider of life sciences software that automates the core functions of drug development with its end-to-end LifeSphere® LifeSphere® technology platform, today announced

NATCO Pharma Limited announces launch of Pomalidomide Capsules in Canada, the first generic alternative to POMALYST® brand in the country approved by Health Canada. Pomalidomide is used in combination with Dexamethasone and Bortezomib for the treatment of adult patients

Tempus, a leader in artificial intelligence (AI) and precision medicine, today announced a multi-year, strategic collaboration with Pfizer in which the two companies are working together to further AI and machine learning-driven efforts in therapeutic development. The goal of this collaboration

AMO Pharma Limited, a privately held biopharmaceutical company focusing on rare childhood-onset neurogenetic disorders with limited or no treatment options, today announced that the UK

Mitsubishi Tanabe Pharma America, Inc. today announced the publication of results from the global, multi-center, open-label, Phase 3 clinical trial evaluating the long-term safety

TransCode Therapeutics, Inc., the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the signing of a non-binding letter of intent and a joint research and development agreement (JDA) with industrial biotechnology and genome editing expert, BRAIN Biotech AG

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today a collaboration and option agreement with Ono Pharmaceutical Co., Ltd. (“Ono”), for CUE-401, a bispecific protein

Pharmatech Associates today announced a strategic alliance that brings PCM expertise and capabilities to the marketplace to tackle drug shortages and supply chain issues by providing drug sponsors and manufacturers a more effective means of making finished drug products